Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11987MR)

This product GTTS-WQ11987MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11987MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5202MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ9256MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ5988MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ9985MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ6499MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ9100MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ11806MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ13856MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW